• Vyome Holdings posted a net loss attributable to common shareholders of USD 720,000, or USD 0.10 a share, for Q2 2026.
• Operating expenses totaled USD 874,000, including USD 507,000 in R&D spending.
• Cash and cash equivalents climbed to USD 7.9 million at June 30, 2026, from USD 5 million at Dec. 31, 2025.
• VT-1953 Phase 2 data showed statistically significant gains in malodor and lesion pain; no treatment-emergent adverse events were reported.
• FDA provided written feedback on VT-1953’s pre-IND package; plans include a Type C meeting to advance the pivotal study strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vyome Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260825277204) on August 25, 2026, and is solely responsible for the information contained therein.